US Nuclear Medicine Market

The US nuclear medicine market is projected to reach USD 9.56 billion by 2030 from USD 4.81 billion in 2025, at a CAGR of 14.7% during the forecast period. The growth is primarily driven by the increasing prevalence of cancer, cardiovascular, and neurological diseases, as it has led to an increased demand for more advanced diagnostic and therapeutic radiopharmaceuticals. Market expansion is also being supported by technological developments in the production of radioisotopes and targeted radioligand treatments. Additionally, the increased use of PET and SPECT imaging in clinical practice, along with the favorable reimbursement of nuclear imaging processes, is driving the market growth. The growth of the US nuclear medicine market is accelerating due to increased investments in the domestic manufacturing of radioisotopes and the continued research in the new theranostics agents.

Product innovation, expansion of portfolio, and strategic partnerships and acquisitions continue to be the most common growth strategies in the US nuclear medicine market. The main competitors, like GE HealthCare and Siemens Healthineers, are working on the constant innovation of imaging systems and radiopharmaceuticals in order to consolidate their competitiveness among diagnostic and therapeutic uses. Additionally, companies such as Novartis, Cardinal Health, and others are focusing on partnerships, acquisitions, and expansion of manufacturing and distribution of the radioisotopes in the US to increase the reliability of the supply of radioisotopes and their accessibility to the markets. All these strategies are geared towards balancing the increasing clinical need of nuclear medicine procedures in the US while maintaining technological progress, compliance, and operational leadership.

To know about the assumptions considered for the study download the pdf brochure

Prominent players in the market include GE HealthCare (US), Cardinal Health (US), Curium (France), Bayer AG (Germany), Lantheus Holdings, Inc. (US), Novartis AG (Switzerland), Jubilant Pharmova Limited (India), Bracco Imaging S.P.A (Italy), Pharmalogic Holdings Corp. (US), Sun Pharmaceutical Industries, Inc. (India), Nordion Inc. (Canada), Siemens Healthineers AG (Germany), NorthStar Medical Radiosiotopes, LLC (US), Eckert & Ziegler (Germany), Actinium Pharmaceuticals, Inc. (US), Global Medical Solutions (US), Telix Pharmaceuticals Limited (Australia), PDRadiopharma Inc. (Japan), ITM Isotope Technologies Munich SE (Germany), BWX Technologies Inc. (US), SHINE Technologies, LLC (US), Isotopia (Israel), IRE Elit (Turkey), Cyclopharm (Australia), and RadioMedix, Inc. (US)

GE HealthCare has a strong presence in the US nuclear medicine market, supported by the presence of one of the largest networks of nuclear pharmacies in the nation and a wide range of FDA-approved radiopharmaceuticals. The company offers diagnostic and therapeutic radioisotopes in major clinical uses, including oncology, cardiology, and neurology, and advanced PET and SPECT systems. The services delivered to hospitals and imaging centers in the US are dependable and time-sensitive due to the integration of capabilities in the radiopharmaceutical production, imaging technologies, and distribution conducted by GE HealthCare. The company is a key enabler of diagnostics and therapies of nuclear medicine in the US because it is highly focused on innovation, theranostics, and workflow efficiency.

In the US nuclear medicine market, Cardinal Health is a significant participant through its Nuclear & Precision Health Solutions business. The company also has a large network of nuclear pharmacies spread across the country that are used to prepare and distribute doses of radiopharmaceuticals used in PET and SPECT procedures. Cardinal Health is a distributor of radiopharmaceuticals and generators, as well as other related products, in addition to offering regulatory support, operational support, and logistics support to health care providers. Its strengths are its ability to supply reliably, regulatory compliance, and deliver on demand, which makes it an essential distribution and service provider of diagnostic and therapeutic nuclear medicine applications across the US.

MARKET RANKING

The US nuclear medicine market is also driven by specialized radiopharmaceutical developers and health care companies that focus on distribution and clinical support of diagnostic and therapeutic procedures in the field of oncology, cardiology, and neurology. GE HealthCare holds a strong position in the market with a firmly established US nuclear pharmacy chain and a wide portfolio of FDA-approved radiopharmaceuticals, which facilitate steady supply and clinical uptake of nuclear diagnostics and interventions. Cardinal Health has an important role to play as it has been involved in nationwide distribution of radiopharmaceuticals, nuclear pharmacy, and operational assistance so that delivery of time-sensitive radioactive doses is made on time. Curium Pharma enables the market to be enhanced with its combined US manufacturing and radiopharmacy presence, which targets both diagnostic and therapeutic radiopharmaceuticals. Bayer AG makes a contribution with its diagnostic nuclear imaging agents, especially in the fields of oncology and cardiology. The combined efforts of these companies contribute to the US nuclear medicine ecosystem by addressing the critical demands in the supply of radiotracers, distribution of radiotracers, imaging infrastructure, and clinical implementation.

Related Reports:

US Nuclear Medicine Market by Type (SPECT [Tc99m, I-123, Ga-67], PET [F-18],  Alpha Emitters, Beta Emitters [Y-90, Lu-177]), Application (Onco, Neuro), Procedure, End User (Imaging Center, Hospital), Radioisotope, Market Share, Growth - Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com